| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Division of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, Texas,
2 Photon Migration Laboratories, Texas A&M University, College Station, Texas
The specificity of a novel epidermal growth factor (EGF)-Cy5.5 fluorescent optical probe in the detection of EGF receptor (EGFr) was assessed using continuous-wave fluorescence imaging accomplished via an intensified charge-coupled device (CCD) camera. Human mammary MDA-MB-468 (EGFr+) and MDA-MB-435 (EGFr-) cancer cells were incubated with Cy5.5, EGF-Cy5.5, or the anti-EGFr monoclonal antibody C225 or EGF followed by EGF-Cy5.5 and examined under a fluorescence microscope. In vivo imaging was performed on mice with s.c. MDA-MB-468 and MDA-MB-435 tumors. Images were obtained every 6 s for 20 min after i.v. injection of each agent and every 24 h after injection for up to 192 h. Additionally, mice with MDA-MB-468 tumors were injected i.v. with C225 24 h before injection of EGF-Cy5.5. EGF-Cy5.5, but not Cy5.5 or indocyanine green dye (ICG), bound to MDA-MB-468 cells. Binding of EGF-Cy5.5 was blocked by C225 and by EGF. In contrast, binding of EGF-Cy5.5 to MDA-MB-435 cells was not observed. Monitoring of the time-fluorescence intensity in mice confirmed that ICG and Cy5.5 had no favorable binding to tumor regardless of EGFr expression level. In contrast, EGF-Cy5.5 accumulated only in MDA-MB-468 tumors. Moreover, tumor uptake of EGF-Cy5.5 was blocked by C225. ICG and Cy5.5 fluorescence was completely absent from the tumor site, regardless of EGFr expression level, 24 h after injection. Little EGF-Cy5.5 fluorescence was detected in MDA-MB-435 tumors 24 h after injection. In MDA-MB-468 tumors, our data suggest that EGF-Cy5.5 may be used as a specific NIR contrast agent for noninvasive imaging of EGFr expression and monitoring of responses to molecularly targeted therapy.
This article has been cited by other articles:
![]() |
J. V. Frangioni New Technologies for Human Cancer Imaging J. Clin. Oncol., August 20, 2008; 26(24): 4012 - 4021. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Diagaradjane, J. M. Orenstein-Cardona, N. E. Colon-Casasnovas, A. Deorukhkar, S. Shentu, N. Kuno, D. L. Schwartz, J. G. Gelovani, and S. Krishnan Imaging Epidermal Growth Factor Receptor Expression In vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe Clin. Cancer Res., February 1, 2008; 14(3): 731 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Peng, R. Liu, M. Andrei, W. Xiao, and K. S. Lam In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against {alpha}4{beta}1 integrin Mol. Cancer Ther., February 1, 2008; 7(2): 432 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Kulbersh, R. D. Duncan, J. S. Magnuson, J. B. Skipper, K. Zinn, and E. L. Rosenthal Sensitivity and Specificity of Fluorescent Immunoguided Neoplasm Detection in Head and Neck Cancer Xenografts Arch Otolaryngol Head Neck Surg, May 1, 2007; 133(5): 511 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Rosenthal, B. D. Kulbersh, T. King, T. R. Chaudhuri, and K. R. Zinn Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts Mol. Cancer Ther., April 1, 2007; 6(4): 1230 - 1238. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Kovar, M. A. Johnson, W. M. Volcheck, J. Chen, and M. A. Simpson Hyaluronidase Expression Induces Prostate Tumor Metastasis in an Orthotopic Mouse Model Am. J. Pathol., October 1, 2006; 169(4): 1415 - 1426. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Reichenberger, R. D. Coletta, A. P. Schulte, M. Varella-Garcia, and H. L. Ford Gene Amplification Is a Mechanism of Six1 Overexpression in Breast Cancer Cancer Res., April 1, 2005; 65(7): 2668 - 2675. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Chen, P. S. Conti, and R. A. Moats In vivo Near-Infrared Fluorescence Imaging of Integrin {alpha}v{beta}3 in Brain Tumor Xenografts Cancer Res., November 1, 2004; 64(21): 8009 - 8014. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chung, S.-O. Yoon, E. A. Lipscomb, and A. M. Mercurio The Met Receptor and {alpha}6{beta}4 Integrin Can Function Independently to Promote Carcinoma Invasion J. Biol. Chem., July 30, 2004; 279(31): 32287 - 32293. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |